---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-013295"
form_type: "8-K"
ticker: "TOI"
cik: "0001799191"
company_name: "Oncology Institute, Inc."
filed_at: "2024-03-27T23:59:59+00:00"
generated_at: "2026-06-04T07:19:08.652275+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# TOI reports Q4 revenue $86M (+20.1% YoY), net loss widens to $18.8M

## Summary
- Q4 2023 revenue $86M (+20.1% YoY); gross profit $14M (-8.0% YoY).
- Net loss $18.8M (vs $11.0M loss in Q4 2022); diluted EPS -$0.21.
- Adjusted EBITDA -$6.3M (vs -$4.6M in prior year quarter).
- Operational: remediated material weakness, signed full-risk contract in South Florida, launched CA pharmacy with 1,300 specialty fills.
- Ended 2023 with 69 clinics, 119 providers; cash $83M. 2024 outlook mentioned but not detailed.

## SEC filing metadata
- accession: 0001628280-24-013295
- form_type: 8-K
- ticker: TOI
- cik: 0001799191
- company_name: Oncology Institute, Inc.
- filed_at: 2024-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799191/000162828024013295/0001628280-24-013295-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799191/000162828024013295/toi-20240327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-013295
- JSON: https://secwatch.observer/filing/0001628280-24-013295.json
- Plain text: https://secwatch.observer/filing/0001628280-24-013295.txt

## Key facts
- Earnings Releases
  Oncology Institute, Inc. reported fourth quarter and fiscal year ended December 31, 2023 results: revenue $86 million, net income $18.8 million, EPS $(0.21).
  - Period: fourth quarter and fiscal year ended December 31, 2023
  - Revenue: $86 million
  - Net income: $18.8 million
  - EPS: $(0.21)
  - Result: reported results
  source text: Officer. • Hired 7 new providers in the quarter and ended the year with 69 clinics and 119 employed providers. Fourth Quarter 2023 Financial Highlights • Consolidated revenue of $86 million, an increase of 20.1% compared to the prior year quarter • Gross profit of $14 million, a decrease of 8.0% compared to the prior year quarter • Net loss of $18.8 million compared
  evidence_url: https://www.sec.gov/Archives/edgar/data/1799191/000162828024013295/0001628280-24-013295-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.